DCPH - Deciphera Pharmaceuticals Inc Stock Price, Fair Value and News

14.19USD-0.43 (-2.94%)Market Closed

Market Summary

USD14.19-0.43

Market Closed

-2.94%

DCPH Stock Price

View Fullscreen

DCPH RSI Chart

DCPH Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-4.55

Price/Sales (Trailing)

7.23

EV/EBITDA

-5.71

Price/Free Cashflow

-8.01

DCPH Price/Sales (Trailing)

DCPH Profitability

EBT Margin

-119.07%

Return on Equity

-73.97%

Return on Assets

-54.82%

Free Cashflow Yield

-12.48%

DCPH Fundamentals

DCPH Revenue

Revenue (TTM)

163.4M

Rev. Growth (Yr)

32.88%

Rev. Growth (Qtr)

11.5%

DCPH Earnings

Earnings (TTM)

-259.6M

Earnings Growth (Yr)

138%

Earnings Growth (Qtr)

135.21%

Breaking Down DCPH Revenue

52 Week Range

12.3016.43

(Low)(High)

Last 7 days

-0.7%

Last 30 days

-4.4%

Last 90 days

1.9%

Trailing 12 Months

0.7%

How does DCPH drawdown profile look like?

DCPH Financial Health

Current Ratio

3.8

DCPH Investor Care

Shares Dilution (1Y)

6.39%

Diluted EPS (TTM)

-2.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	138.3M	144.1M	151.4M	163.4M
2022	100.2M	109.1M	121.9M	134.0M
2021	67.2M	83.7M	91.4M	96.1M
2020	0	30.7M	36.4M	42.1M
2019	0	0	0	25.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Deciphera Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	brightstar associates llc	acquired	481	0.01	48,136	-
Feb 16, 2024	kelly thomas patrick	sold	-47,009	15.6177	-3,010	chief financial officer
Feb 16, 2024	pitman jama	sold	-35,405	15.6176	-2,267	svp, chief development officer
Feb 16, 2024	sherman matthew l	sold	-40,840	15.6177	-2,615	evp & chief medical officer
Feb 16, 2024	martin daniel c.	sold	-35,405	15.6176	-2,267	chief commercial officer
Feb 15, 2024	sherman matthew l	acquired	-	-	17,275	evp & chief medical officer
Feb 15, 2024	kelly thomas patrick	acquired	-	-	17,275	chief financial officer
Feb 15, 2024	martin daniel c.	acquired	-	-	9,725	chief commercial officer
Feb 15, 2024	pitman jama	acquired	-	-	19,725	svp, chief development officer
Feb 15, 2024	dhanak dashyant	acquired	-	-	17,275	evp & chief scientific officer

Which funds bought or sold DCPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-66.18	-58,000	29,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	127	1,573	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	92,821	439,059	-%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-40.00	-4,000	4,000	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-1.83	-14,718	330,173	-%
Apr 18, 2024	Diversified Trust Co	added	6.5	7,451	200,510	0.01%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	2,000	-%
Apr 18, 2024	Edmonds Duncan Registered Investment Advisors, LLC	unchanged	-	-7,099	279,160	0.07%
Apr 15, 2024	Legato Capital Management LLC	new	-	827,964	827,964	0.10%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	71.43	113,199	281,709	0.01%

Are Funds Buying or Selling DCPH?

Are funds buying DCPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DCPH

No. of Funds

Unveiling Deciphera Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	braidwell lp	2.92%	2,385,623	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.49%	5,200,000	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	8,359,768	SC 13G/A
Feb 13, 2024	vanguard group inc	5.49%	4,401,636	SC 13G/A
Feb 12, 2024	flynn james e	7.19%	5,788,024	SC 13G/A
Feb 09, 2024	brightstar associates llc	28.2%	23,059,708	SC 13G/A
Feb 06, 2024	goldman sachs group inc	2.5%	2,007,447	SC 13G/A
Jan 26, 2024	blackrock inc.	7.5%	5,976,266	SC 13G/A
Jan 23, 2024	state street corp	3.08%	2,470,813	SC 13G/A
Mar 22, 2023	flynn james e	6.09%	4,627,310	SC 13G

Recent SEC filings of Deciphera Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 22, 2024	PRER14A	PRER14A
Apr 11, 2024	PRE 14A	PRE 14A
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Deciphera Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-4.29%	-10.06%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	1.36%	9.00%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-4.27%	-33.23%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-2.78%	11.49%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.58%	-21.63%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-7.47%	58.08%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	0.71%	-13.71%	-333.24	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-9.74%	-19.21%	11.58	2.48	49.61%	324.78%
BHC	3.1B	8.8B	-9.70%	20.22%	-5.28	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.03%	4.38%	14.34	3.06	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-14.42%	-17.86%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-15.72%	-46.54%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-17.24%	40.47%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-33.33%	-94.15%	-0.19	0.14	80.00%	43.08%
ACOR	683.2K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Deciphera Pharmaceuticals Inc News

Latest updates

Deciphera Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2
Revenue	11.5%	48,294,000	43,313,000	38,304,000	33,445,000	36,345,000	35,974,000	32,494,000	29,223,000	24,199,000	23,220,000	23,573,000	25,156,000	19,486,000	15,449,000	7,090,000	13,060,000	19,030,000	25,000,000
Costs and Expenses	2.6%	99,532,000	97,001,000	91,079,000	86,702,000	83,506,000	80,855,000	76,282,000	76,115,000	112,600,000	102,888,000	94,087,000	86,650,000	82,485,000	79,446,000	76,022,000	70,373,000	58,353,000	47,975,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70,373,000	58,353,000	47,975,000
S&GA Expenses	17.7%	39,148,000	33,252,000	32,610,000	31,449,000	32,195,000	30,026,000	29,625,000	28,321,000	37,151,000	35,527,000	32,828,000	30,747,000	30,070,000	30,143,000	29,933,000	23,737,000	17,979,000	13,164,000
R&D Expenses	-6.2%	58,599,000	62,463,000	58,296,000	54,765,000	48,066,000	47,485,000	44,858,000	47,412,000	74,931,000	66,444,000	59,984,000	55,681,000	52,288,000	49,213,000	46,081,000	46,636,000	40,374,000	34,811,000
EBITDA Margin	-Infinity%	-1.18	-	-1.22	-1.27	-1.31	-2.44	-2.72	-2.96	-3.09	-2.88	-3.15	-3.93	-6.28	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,000	17,000	25,000
EBT Margin	-Infinity%	-1.19	-	-1.24	-1.29	-1.33	-2.46	-2.75	-2.99	-3.12	-2.91	-3.19	-3.97	-6.33	-	-	-	-	-
Net Income	135.2%	17,455,500	-49,581,000	-48,562,000	-178,900,000	-45,935,000	-43,043,000	-43,061,000	-46,892,000	-88,395,000	-79,838,000	-70,433,000	-61,298,000	-62,740,000	-63,701,000	-67,241,000	-67,216,000	-56,196,000	-21,460,000
Net Income Margin	25.5%	-1.59	-2.13	-2.20	-2.25	-1.33	-1.82	-2.37	-2.85	-3.12	-3.00	-3.09	-3.80	-	-	-	-	-	-
Free Cashflow	3.3%	-28,872,000	-29,869,000	-38,919,000	-49,815,000	-35,139,000	-21,401,000	-45,811,000	-51,352,000	-66,067,000	-56,009,000	-52,399,000	-68,319,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.9%	474	498	510	549	454	476	507	385	429	483	541	595	642	660	686	733	622	650	260	270	316
Current Assets	-8.7%	381	418	405	476	393	421	449	320	339	385	437	547	584	571	633	703	593	642	256	266	301
Cash Equivalents	-22.7%	84.00	108	81.00	115	65.00	83.00	110	95.00	87.00	53.00	91.00	202	136	111	155	230	120	174	57.00	82.00	294
Inventory	-21.7%	21.00	27.00	25.00	26.00	21.00	19.00	21.00	20.00	14.00	7.00	8.00	7.00	6.00	5.00	1.00	-	-	-	-	-	-
Net PPE	-7.6%	5.00	6.00	6.00	7.00	7.00	7.00	7.00	8.00	9.00	11.00	10.00	10.00	10.00	10.00	10.00	7.00	6.00	5.00	2.00	2.00	13.00
Liabilities	5.6%	123	116	105	109	112	102	102	114	125	103	94.00	92.00	99.00	91.00	67.00	61.00	76.00	44.00	37.00	30.00	36.00
Current Liabilities	7.9%	100	93.00	81.00	84.00	86.00	75.00	75.00	87.00	97.00	76.00	66.00	64.00	70.00	61.00	51.00	45.00	60.00	42.00	35.00	28.00	23.00
Shareholder's Equity	-8.1%	351	382	404	440	342	374	405	272	305	380	447	503	544	569	620	672	546	606	223	240	280
Retained Earnings	0%	-1,400	-1,400	-1,300	-1,282	-1,233	-1,200	-1,144	-1,101	-1,054	-966	-886	-815	-754	-691	-628	-560	-487	-420	-364	-343	-295
Additional Paid-In Capital	0.8%	1,778	1,763	1,736	1,722	1,575	1,563	1,550	1,373	1,359	1,346	1,332	1,318	1,298	1,260	1,247	1,232	1,034	1,026	587	583	575
Shares Outstanding	0.7%	81.00	80.00	79.00	79.00	68.00	73.00	68.00	59.00	58.00	58.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	777	-	-	-	636	-	-	-	1,504	-	-	-	2,347	-	-	-	446	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.3%	-28,809	-29,807	-38,626	-49,455	-35,158	-20,828	-45,524	-51,352	-67,176	-53,999	-51,967	-67,682	-49,128	-49,341	-60,844	-80,370	-55,833	-23,191	-37,266	-33,006	-26,868
Share Based Compensation	26.1%	14,073	11,160	12,856	12,514	12,313	12,373	12,988	14,268	10,794	11,794	12,371	11,119	9,706	9,828	10,609	6,994	5,345	4,729	4,107	6,229	2,805
Cashflow From Investing	-94.7%	2,199	41,403	4,361	-35,414	16,304	-6,071	-104,194	59,652	98,952	14,441	-60,453	123,908	46,079	1,821	-17,751	-1,690	1,680	-294,810	12,256	-179,648	-303
Cashflow From Financing	-94.3%	890	15,590	838	134,686	478	209	164,224	83.00	1,978	1,706	1,682	9,524	27,792	3,228	4,389	191,392	761	434,476	19.00	1,118	60.00

DCPH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Total revenues	$ 163,356	$ 134,036	$ 96,148
Cost and operating expenses:
Cost of sales	3,732	8,770	2,932
Research and development	234,123	187,821	257,040
Selling, general, and administrative	136,459	120,167	136,253
Total cost and operating expenses	374,314	316,758	396,225
Loss from operations	(210,958)	(182,722)	(300,077)
Other income (expense):
Interest and other income, net	16,447	4,513	113
Total other income (expense), net	16,447	4,513	113
Loss before income tax expense	(194,511)	(178,209)	(299,964)
Income tax expense	431	722	0
Net loss	$ (194,942)	$ (178,931)	$ (299,964)
Net loss per share - basic (in dollars per share)	$ (2.29)	$ (2.37)	$ (5.16)
Net loss per share - diluted (in dollars per share)	$ (2.29)	$ (2.37)	$ (5.16)
Weighted average common shares outstanding - basic (in shares)	85,059,962	75,500,148	58,084,325
Weighted average common shares outstanding - diluted (in shares)	85,059,962	75,500,148	58,084,325
Comprehensive loss:
Net loss	$ (194,942)	$ (178,931)	$ (299,964)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities	1,043	(992)	(278)
Currency translation adjustment	517	(42)	318
Total other comprehensive income (loss)	1,560	(1,034)	40
Total comprehensive loss	$ (193,382)	$ (179,965)	$ (299,924)

DCPH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 83,507	$ 64,741
Short-term marketable securities	222,709	259,745
Accounts receivable, net	31,952	22,429
Inventory	21,210	20,561
Prepaid expenses and other current assets	21,718	25,482
Total current assets	381,096	392,958
Long-term marketable securities	46,699	14,550
Long-term investments—restricted and other long-term assets	8,277	3,277
Property and equipment, net	5,421	6,707
Operating lease assets	32,073	36,547
Total assets	473,566	454,039
Current liabilities:
Accounts payable	26,476	18,612
Accrued expenses and other current liabilities	70,295	64,622
Operating lease liabilities	3,504	3,235
Total current liabilities	100,275	86,469
Operating lease liabilities, net of current portion	22,375	25,879
Total liabilities	122,650	112,348
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 80,503,338 shares and 67,637,351 shares issued and outstanding as of December 31, 2023 and 2022, respectively	805	676
Additional paid-in capital	1,777,839	1,575,361
Accumulated other comprehensive income	577	(983)
Accumulated deficit	(1,428,305)	(1,233,363)
Total stockholders' equity	350,916	341,691
Total liabilities and stockholders' equity	$ 473,566	$ 454,039

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Steven L. Hoerter
WEBSITE	deciphera.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	300

Deciphera Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Deciphera Pharmaceuticals Inc? What does DCPH stand for in stocks?

DCPH is the stock ticker symbol of Deciphera Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Deciphera Pharmaceuticals Inc (DCPH)?

As of Wed Apr 24 2024, market cap of Deciphera Pharmaceuticals Inc is 1.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCPH stock?

You can check DCPH's fair value in chart for subscribers.

What is the fair value of DCPH stock?

You can check DCPH's fair value in chart for subscribers. The fair value of Deciphera Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Deciphera Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DCPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Deciphera Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether DCPH is over valued or under valued. Whether Deciphera Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Deciphera Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCPH.

What is Deciphera Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, DCPH's PE ratio (Price to Earnings) is -4.55 and Price to Sales (PS) ratio is 7.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCPH PE ratio will change depending on the future growth rate expectations of investors.